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Attention deficit/hyperactivity disorder (ADHD) is a common heritable disorder with a childhood onset. Molecular
genetic studies of ADHD have previously focused on examining the roles of specific candidate genes, primarily
those involved in dopaminergic pathways. We have performed the first systematic genomewide linkage scan for
loci influencing ADHD in 126 affected sib pairs, using a ∼10-cM grid of microsatellite markers. Allele-sharing
linkage methods enabled us to exclude any loci with a ls of 3 from 96% of the genome and those with a ls of
2.5 from 91%, indicating that there is unlikely to be a major gene involved in ADHD susceptibility in our sample.
Under a strict diagnostic scheme we could exclude all screened regions of the X chromosome for a locus-specific
ls of 2 in brother-brother pairs, demonstrating that the excess of affected males with ADHD is probably not
attributable to a major X-linked effect. Qualitative trait maximum LOD score analyses pointed to a number of
chromosomal sites that may contain genetic risk factors of moderate effect. None exceeded genomewide significance
thresholds, but LOD scores were 11.5 for regions on 5p12, 10q26, 12q23, and 16p13. Quantitative-trait analysis
of ADHD symptom counts implicated a region on 12p13 (maximum LOD 2.6) that also yielded a LOD 11 when
qualitative methods were used. A survey of regions containing 36 genes that have been proposed as candidates for
ADHD indicated that 29 of these genes, including DRD4 and DAT1, could be excluded for a ls of 2. Only three
of the candidates—DRD5, 5HTT, and CALCYON—coincided with sites of positive linkage identified by our screen.
Two of the regions highlighted in the present study, 2q24 and 16p13, coincided with the top linkage peaks reported
by a recent genome-scan study of autistic sib pairs.
Introduction
Attention deficit/hyperactivity disorder (ADHD [MIM
143465]) is a common neurobehavioral disorder affecting
∼5%–10% of children and adolescents and 3% of
adults (Wolraich et al. 1996; Swanson et al. 1998; Scahill
and Schwab-Stone 2000; Brown et al. 2001). It is a con-
dition characterized by behavioral symptoms of inatten-
tion and/or hyperactivity-impulsivity, with onset in child-
hood and significant impairment in two or more settings
(American Psychiatric Association 1994). Such symptoms
include restlessness, difficulty with organizing tasks, dis-
tractibility, forgetfulness, difficulty awaiting turns, and
frequent interrupting. Under the most recent diagnostic
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system, DSM-IV (American Psychiatric Association
1994), children may be classified with one of three sub-
types—inattentive (I), hyperactive-impulsive (HI) or com-
bined (C)—on the basis of whether they exceed symptom
thresholds for I dimensions, HI dimensions, or both, re-
spectively. The disorder is diagnosed more often in boys
than in girls, with a ratio of 3–4:1 (Cantwell 1996; Swan-
son et al. 1998). Of ADHD cases, 60% occur with
another major psychiatric disorder or learning disability
(Cantwell 1996). On the basis of a review of the literature,
Brown and colleagues (2001) found that the conditions
most commonly comorbidwith ADHDwere oppositional
defiant disorder (ODD) (33%), conduct disorder (CD)
(25%), anxiety disorders (25%), depressive disorders
(20%), and learning disabilities (22%).
Numerous investigations have supported a significant
role for genetic influences in the etiology of ADHD(Smal-
ley 1997). Family studies indicate a sibling relative risk
(ls) of ∼5 for this common disorder (Biederman et al.
1992). Over the past 6 years, 15,000 twin pairs from
unselected population samples in the United States,
United Kingdom, Norway, and Australia have been as-
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sessed for behavioral symptoms of inattention and hy-
peractivity-impulsivity, as well as for clinical diagnoses
of ADHD (Edelbrock et al. 1995; Thapar et al. 1995;
Gjone et al. 1996; Levy et al. 1997; Sherman et al. 1997;
Hudziak et al. 1998; Eaves et al. 2000, Thapar et al.
2000). Heritability estimates from these studies havebeen
consistently high, generally falling in the 60%–80%
range, whether the evaluation is of qualitatively diag-
nosed ADHD or quantitative measures of behavioral di-
mensions correlated with ADHD.
Data from two epidemiologically based twin studies
have suggested that a significant proportion of the ge-
netic influences underlying ADHD may be contributing
independently to the HI and I symptom dimensions,
implying that there are unique (as well as shared) genetic
effects for different subtypes (Sherman et al. 1997; Hud-
ziak et al. 1998). In contrast, it has been found that, in
families containing multiple individuals affected with
ADHD, the I, HI, and C subtypes do not tend to “breed
true,” with a general lack of sibling similarity for each
of the two separate symptom dimensions (Smalley et al.
2000). Therefore, the family-based studies appear to
imply that—although there may be unique genetic ef-
fects—the majority of genetic liability is shared between
subtypes. It may be that differences in ascertainment or
diagnostic procedure are partly responsible for the dis-
tinct conclusions of the twin- and family-based studies.
Alternatively, it is possible that unique genetic variance
is smaller in extreme selected samples. The Smalley et
al. (2000) sample was identified through volunteer re-
sponses to advertisements and may reflect a clinically
severe population of ADHD families, compared with
population-based twin samples. In the present report,
we present molecular genetic investigations of a subset
of affected sib pairs (ASPs) taken from the Smalley et
al. (2000) sample of multiplex families.
To date, all previous molecular genetic studies of
ADHD have targeted specific candidate genes for in-
vestigation, mainly through case-control and/or family-
based association strategies. In general, candidate genes
have been chosen on the basis of models of effective
psychopharmacological intervention for treating the
disorder. There is a 60%–80% response rate of children
and adolescents with ADHDwhen given stimulants that
target dopamine transport, release and reuptake (Spen-
cer et al. 1996). In addition, knockout mice that com-
pletely lack the dopamine transporter gene (DAT1)
demonstrate extreme hyperactivity (Giros et al. 1996).
Most molecular genetic studies of ADHDhave therefore
focused on genes encoding proteins that are involved in
the dopaminergic system, including DAT1, the dopa-
mine receptors DRD2-5, dopa decarboxylase (DDC),
dopamine beta-hydroxylase (DBH), and monoamine
oxidase A (MAOA) (e.g., Cook et al. 1995; LaHoste et
al. 1996; Gill et al. 1997; Smalley et al. 1998; Daly et
al. 1999; McCracken et al. 2000; Barr et al. 2001; Far-
aone et al. 2001; Payton et al. 2001). Genes implicated
in other systems, such as the serotonin processing path-
way, have also been suggested as candidates for ADHD
(Manor et al. 2001). Of all the candidate genes inves-
tigated thus far, the strongest evidence for association
with ADHD has been found for polymorphisms in the
DRD4 (LaHoste et al. 1996; Smalley et al. 1998; Far-
aone et al. 2001; Mill et al. 2001) and DAT1 (Cook et
al. 1995; Gill et al. 1997; Daly et al. 1999) genes. Nev-
ertheless, in each case there have been several studies
that have not supported association (e.g., Palmer et al.
1999; Holmes et al. 2000), and the effect sizes of the
putative risk alleles are estimated to be rather small (e.g.,
genotype relative risks 1.1–1.9 [Daly et al. 1999; Curran
et al. 2001; Faraone et al. 2001]).
A complementary strategy for pinpointing genetic
risk factors involved in ADHD susceptibility is to per-
form a systematic genomewide scan of affected subjects,
using high-throughput genotyping technology. Al-
though association-based methods are likely to be able
to identify genes of very small effect, it is not yet prac-
tical to undertake this kind of analysis on a genomewide
scale in outbred populations. First, to ensure a reason-
able chance of detecting risk loci, such approaches re-
quire a prohibitively high density of markers (on the
order of 1–20 markers/cM). Second, association-based
methods are complicated by variation in the extent of
linkage disequilibrium in different chromosomal regions
and in different populations. Linkage-based methods
offer a feasible alternative, needing only a relatively low
density of evenly spaced markers (∼1 every 10–20 cM).
Linkage has proved to be a successful way to map both
Mendelian and genetically complex traits, with the ca-
veat that loci of minor effect are unlikely to be detected
unless extremely large samples are investigated.
A segregation analysis of extended pedigrees by Far-
aone and colleagues (1992) previously suggested that a
major gene may contribute to genetic liability for
ADHD. As discussed above, although several candidate
genes have been proposed to influence ADHD, their
estimated effect sizes are very small. Furthermore, prior
to the current investigation, no genomewide molecular
studies have been used to explore the possibility of a
major gene effect in this disorder. Thus, if a major risk
gene does indeed exist for ADHD, it has yet to be iden-
tified. We have performed the first linkage-based ge-
nomewide scan for loci involved in ADHD in a sample
of 126 ASPs, using microsatellite markers with an av-
erage spacing of ∼10 cM. The ASP design allowed us
to apply nonparametric allele-sharing methods, which
do not rely on assumptions about the underlying genetic
model for detection of linkage. Using such methods, a
sample of one hundred affected sib pairs provides 190%
power to detect a major gene effect ( ), if a LOD-l 1 3.5s
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Table 1
ASP Families Included in the
Genomewide Scan
Subjects n
Families:
Two affected sibs 96
Three affected sibs 6
Four affected sibs 2
Total 104
Sib pairs:
Completely independenta 114
Allb 126
a A family with n sibs contrib-
utes independent pairs.n 1
b A family with n sibs contrib-
utes possible pairs.n(n 1)/2
score threshold of 3.0 is employed (Risch 1990). When
a less stringent LOD-score threshold of 1.0 is adopted,
the same sample size yields 190% power to detect sus-
ceptibility loci with smaller effects ( ), althoughl p 2.0s
the reduced threshold is accompanied by an increase in
type I–error rate (Weeks and Lathrop 1995). In addi-
tion, although all sibs in the present study had a positive
diagnosis of ADHD, the severity of disorder was vari-
able, and this was partly accounted for by familial fac-
tors. We therefore used a measure of total ADHD symp-
tom count for quantitative trait locus (QTL) analysis,
to search for genetic loci that might modify the severity
of disorder within the ASP sample. Our study indicates
that there is unlikely to be a major gene effect contrib-
uting to ADHD susceptibility but points to a number
of chromosomal regions that may harbor genes of more
moderate effect. These loci require further investigation
in additional samples.
Subjects and Methods
Initial Ascertainment of Sample
Families were identified through clinics, hospitals,
schools, and community organizations in the greater Los
Angeles area, as part of an ongoing molecular genetic
study of ADHD. The majority of families were initially
ascertained through advertisements requesting the partic-
ipation of families with at least two children 5 years of
age showing symptoms of ADHD. An additional 18 fam-
ilies were selected from a previous family study of ADHD
because theywere each known to contain anASP. Families
visited UCLA for evaluation, and, during their first visit,
parents signed consent forms and children signed assent
forms approved by the UCLA Institutional ReviewBoard.
Diagnostic Instruments and Procedures
Assessment of psychiatric disorders, including ADHD,
was performed using a semistructured interview, the
Schedule for Affective Disorders and Schizophrenia for
School-Age Children-Present and Lifetime version
(KSADS-PL) (Kaufman et al. 1997). This was adminis-
tered to themother andwas followed by a direct interview
with the child if he or she was 8 years of age. All in-
terviews were conducted by clinical psychologists or
highly trained interviewers, with extensive experience and
reliability training in psychiatric assessment. Additional
measures employed included the parent and teacher ver-
sions of the SNAP-IV (Swanson 1995), the Child Behavior
Checklist, and the Teacher’s Report Form (Achenbach
1993). Teacher’s Report Forms were used to supplement
information obtained in the direct interview. A best es-
timate procedure, using all available information,was em-
ployed to determine diagnoses, with senior psychiatrists
(J.J.M. and J.T.M.) reviewing positive diagnoses in a
weekly case-review meeting. The mean weighted kappa
for psychiatric diagnoses was .84 (SD .14), with values
of 1.0, .93, and 1.0 for ADHD, ODD, and CD, respec-
tively. ADHD was diagnosed by DSM-IV criteria. A di-
agnosis was defined as “definite” when all criteria were
met (i.e., at least six of nine symptoms on HI and/or I
dimensions, accompanied by significant impairment in
two or more settings) and as “probable” when subjects
fell one symptom short but met the criterion for impair-
ment. Other psychiatric disorders were based on lifetime
diagnoses made by use of DSM-IV criteria (or DSM-IIIR,
in the case of the 18 families drawn from the earlier family
study). Families were excluded from the study if a child
affected with ADHD also met criteria for schizophrenia
or autism. However, other psychiatric diagnoses (such as
ODD or CD) and/or evidence of specific learning disa-
bilities were not grounds for exclusion. Full scale IQ was
determined by use of the WISC-III (Weschler 1991), and
academic achievement was assessed using the Peabody
Individual Achievement Test-Revised (Markwardt 1989).
Children with full-scale IQs !70 were excluded from the
study. A more detailed description of the sample andmea-
sures is given by Smalley et al. (2000)
Demographic and Clinical Characteristics
The genome-scan sample comprised 104 families as-
certained as described above. Several families included
more than two affected siblings (table 1), yielding a total
of 126 possible ASPs for analysis. Table 2 summarizes
the demographic and clinical characteristics of the af-
fected siblings in the sample. The distribution of males
to females (3:1) was similar to that observed in epide-
miological studies of ADHD (Cantwell 1996; Swanson
et al. 1998). The sample was largely white (84%), with
the greatest representation of families in socioeconomic
classes II and III (67%). Themean age of affected siblings
was 11 years (SD 4), and the mean full scale IQ of 105
(SD 14) was above the population average. Five subjects
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Table 2
Demographics and Clinical Characteristics of 218 Affected Siblings
Characteristic
No. of
Affected
Siblings
% of
Sample
Sex:
Male 158 72
Female 60 28
Ethnicity:
White 183 84
Latino 14 7
Asian 5 2
Othera 16 7
SESb:
I 39 18
II 78 36
III 69 31
IV 28 13
V 4 2
ADHD diagnosis:
Definite 205 94
Probable 13 6
ADHD subtype:
Cc 117 54
Id 87 40
HIe 14 6
Comorbidity:
ODD 95 44
CD 45 21
Moodf 44 20
Anxietyg 28 13
a Includes parents of different ethnicity.
b According to Hollingshead (1957).
c C cases exceed symptom thresholds in both I and HI domains.
d I cases exceed symptom thresholds in the I domain, but not in the
HI domain.
e HI cases exceed symptom thresholds in the HI domain, but not
in the I domain.
f A mood disorder includes major depression, dysthymia, and/or
bipolar disorder. Three cases of ADHDwere also affected with bipolar
disorder, but none were in the same ASP.
g An anxiety disorder includes two or more of the following: panic
disorder, social or simple phobia, obsessive-compulsive disorder, and/
or agoraphobia.
scored in the 70–80 range, but none of these were from
the same ASP family. The majority (94%) of the ASP
members met “definite” criteria for ADHD, and each
family included at least one child with a “definite” di-
agnosis. The distribution of subtypes among the affected
siblings was similar to that observed in epidemiological
studies of ADHD, as were the frequencies of comorbid
psychiatric disorders (Brown et al. 2001). The 126 ASPs
included 66 brother-brother, 54 brother-sister, and 6 sis-
ter-sister pairs.
Genotyping
In children and parents from each family, 404 highly
polymorphic markers, spanning all 22 autosomes and
the X chromosome, were genotyped. Seven families in-
cluded only one parent; the remaining 97 families in-
cluded both. The majority of autosomal markers were
taken from the ABI PRISM LMS2-MD10 panels (Ap-
plied Biosystems), whereas the X-chromosome markers
came from the CHLC (Cooperative Human Linkage
Center)/Weber Human Screening Set Version 6 (Re-
search Genetics). Sex-averaged marker maps were de-
rived primarily from the CHLC, were supplemented
with data from Ge´ne´thon (Dib et al. 1996), and were
verified by comparison to maps estimated from the fam-
ily sample. For autosomal markers, semiautomated fluo-
rescent genotyping was performed by use of standard
techniques, as described by Fisher et al. (1999). For X-
linked genotyping, pooled PCR products were electro-
phoresed on a LICOR apparatus GeneReadIR 4200, and
gel images were analyzed with Saga Genotyping Soft-
ware version 1.0 (University of Washington). Raw allele-
size data were checked for Mendelian inheritance and
were converted to LINKAGE format by use of the GAS
software package (version 2.0) (A. Young, Oxford Uni-
versity). The Discovery Manager (Genomica) database
system was used for storage of genotypic and phenotypic
data and for exporting files in the appropriate format
for statistical analysis. As a final check on genotyping
quality, marker haplotypes were generated from the data
by use of Genehunter version 2.0 (Kruglyak et al. 1996),
to identify any chromosomes showing an excessive num-
ber of recombination events. Allele frequencies were es-
timated from all founders in the sample.
Qualitative ASP Linkage Analysis
Singlepoint and multipoint sib-pair based linkage
analyses of genotype data were performed under two
qualitative classification schemes. We defined “broad”
ADHD as when all sibs have a probable or definite DSM-
IV diagnosis of ADHD (see above), which yielded a total
of 126 pairs. A “narrow” definition reflectedASPswhere
all sibs met a definite diagnosis, yielding a subset of 110
pairs. Autosomal markers were analyzed by use of the
Mapmaker/SIBS options (Kruglyak and Lander 1995)
available in version 2.0 of the Genehunter software
package (Kruglyak et al. 1996). Linkage was assessed
by the maximum LOD score (MLS) method (Risch
1990), as implemented by the “estimate” command of
Genehunter2.0. This involved comparison of maximum-
likelihood estimates of allele-sharing proportions, de-
rived under the restrictions of the “possible triangle”
(Holmans 1993), to those under the null hypothesis of
no linkage. Exclusion mapping was performed under a
series of locus-specific values of ls, under the assumption
of no dominance variance, using the “exclude” com-
mand of Genehunter 2.0. For X-chromosome markers,
MLS and exclusion-mapping methods were run using
the X-linked “estimate” and “exclude” options of the
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Mapmaker/SIBS software package (Cordell et al. 1995;
Kruglyak and Lander 1995). The X-linked MLS ap-
proach employed independent estimation of allele-shar-
ing proportions in brother-brother, brother-sister, and
sister-sister pairs, given the genetic restrictions described
by Cordell et al. (1995), and the overall LOD score was
taken as the sum of the separate LOD scores from each
type of pair. For X-linked exclusion under a series of
locus-specific values of ls, brother-brother, brother-sister,
and sister-sister pairs were again considered separately,
assuming no dominance variance, and LOD scores were
summed for the three groups, yielding an overall esti-
mate for evidence of exclusion. Details of the relation-
ships between allele sharing proportions and values of
ls for each type of pairing in the X-linked situation are
given by Cordell et al. (1995). All analyses utilized all
possible sibling pairs with no weighting schemes. Mul-
tipoint methods employed a 1-cM increment for IBD
scanning.
Quantitative Trait Linkage Analysis
A quantitative measure of severity was defined from
the total DSM-IV symptom count (D4-TOT) on the 18
ADHD symptoms (9 HI and 9 I) generated from the
clinical interview. These symptom counts were derived
from lifetime behaviors (in the worst time period, gen-
erally that between 7 and 12 years of age). We did not
use data from the parent questionnaires (e.g., SNAP-IV)
for direct QTL analyses in these initial investigations,
since these were based on current behaviors and may be
influenced by factors such as medication use, as well as
by maternal report bias (Smalley et al. 2000). Although
all siblings had a “broad” diagnosis of ADHD, there
was still variability in symptom severity as indexed by
D4-TOT (mean 13.3; SD 2.9). There was evidence to
indicate that familial factors contribute to this variabil-
ity; the proportion of variance attributable to such fac-
tors was estimated to be ∼24% in this sample. As a
consequence of subtype distribution, much of the vari-
ability in D4-TOT was a function of variability in the
occurrence of HI symptoms. Specifically, although 94%
of the sample were positive for at least five of nine I
symptoms, only 60% were positive for five or more HI
symptoms. (see table 2).
QTL analysis was performed via traditionalHaseman-
Elston (HE) regression of sib-pair squared trait differ-
ences against estimated IBD sharing (Haseman and Els-
ton 1972), using the Genehunter 2.0 package. The HE
approach has been validated in numerous studies and is
generally robust to variation in ascertainment schemes.
Variance components–based strategies were not em-
ployed in the present study; these rely on multivariate
normality assumptions that are likely to be violated by
our ASP sample and may lead to reduced power and/or
elevated type I error (Allison et al. 1999). X-linked HE
analyses were performed by use of Mapmaker/SIBS
(Kruglyak and Lander 1995). As for qualitative analyses,
the quantitative approach employed all possible sibling
pairs with no weighting schemes and a 1-cM increment
was used for IBD scanning.
In the present study, we have followed the recom-
mendation of Elston (1997) by reporting preciseP values
without adjustment for multiple comparisons, so that
they can be properly interpreted by the reader. The three
different phenotypes investigated here (two overlapping
classification schemes for qualitative analyses and a re-
lated measure for quantitative analyses) are correlated,
so that a Bonferroni correction (which assumes inde-
pendence of tests) would be too conservative.
Results
MLS Analyses
In single-point MLS analysis, one marker, D5S418 on
5p12, yielded a LOD score of 12, whereas additional
markers on 2q, 4p, 7p, 9q, 10q, 12p, 12q, 13q, and Xp
gave LODs 11 (table 3). Multipoint data implicated the
same regions of 5p, 9q, 10q, 12q, 13q, and Xp as those
highlighted by single-point analyses (fig. 1a). Multipoint
LOD scores also exceeded 1 on chromosomes 11q and
16p (table 4). Three of the regions suggested by multi-
point analyses—10q26, 12q23, and 16p13—yielded
peak LOD scores of 11.5 under at least one diagnostic
scheme (table 4). For X-linked MLS analyses the overall
LOD score is taken as the sum of those separately cal-
culated for brother-brother, brother-sister, and sister-sis-
ter pairings, since the allele-sharing restrictions differ for
each type of pair (Cordell et al. 1995; see “Subjects and
Methods” section). The Xp22 linkage identified in the
ADHD ASP sample (tables 3 and 4) arose exclusively
from the brother-sister pairings.
QTL Analyses
Investigation of the D4-TOT quantitative measure
yielded LOD scores 11 for markers on 3q, 8p, 12p, 13q,
16q, and 21q in single-point analysis (table 3). The 8p,
12p, and 13q regions also yielded LODs 11 when mul-
tipoint data were used, with a peak LOD score of 2.6
in 12p13 (table 4; fig. 1b).
Exclusion Mapping
Sib-pair exclusion mapping involves calculation of the
expected allele sharing proportions of a particular locus,
under the assumption of a given locus-specific ls. The
likelihood of the genotype data assuming this ls is com-
pared to the likelihood under the null hypothesis of no
linkage. If the resulting LOD score is !2, this is tra-
ditionally taken as evidence for exclusion of the region
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Table 3
Genome-Scan Markers Yielding Single-Point LOD Scores 1 in MLS or QTL Analyses of ADHD ASPs
CHROMOSOME
POSITION
(cM)a
MOST LIKELY
CYTOGENETIC
LOCATIONb MARKER
HETEROZYGOSITY
(%)c
VALUE IN MLS ANALYSIS
UNDER DIAGNOSTIC SCHEME
Narrow Broad
QTL
D4-TOT
LOD Pd LOD Pd LOD Pd
2 139 2q14 D2S347 74 1.01 .0153 .85 .0238
184 2q24 D2S2330 86 .96 .0178 1.00 .0159
3 169 3q24 D3S1569 83 1.37 .0060
4 25 4p15 D4S403 81 1.22 .0089
5 68 5p12 D5S418 85 1.88 .0016 2.10 .0009
7 41 7p15 D7S516 76 1.24 .0085 1.23 .0087
8 0 8p23 D8S504 76 1.10 .0120
9 85 9q21 D9S167 85 1.22 .0089 .99 .0162
97 9q22 D9S283 80 1.45 .0048 1.16 .0104
10 193 10q26 D10S212 60 .98 .0167 1.11 .0120
12 10 12p13 D12S1725 81 1.59 .0034
22 12p13 D12S336 67 1.07 .0132 .77 .0300 .83 .0253
138 12q24 D12S79 87 1.11 .0119 .95 .0184
165 12q24 D12S324 67 .93 .0190 1.01 .0154
13 0 13q12 D13S175 75 1.33 .0067 1.02 .0151
63 13q31 D13S170 88 1.04 .0143
103 13q33 D13S1265 86 1.49 .0044
16 77 16q21 D16S503 80 1.03 .0147
21 21 21q21 D21S263 75 1.02 .0151
X 0 Xp22 DXS9895 75 1.12 .0116 1.27 .0079
NOTE.—The table lists only those markers that gave a LOD 1 in at least one of the three analyses (narrow, broad, or D4-TOT).
For these markers, LOD scores and P values are shown for all analyses yielding .P ! .05
a Haldane centimorgans from the most p-terminal genome-scan marker of the chromosome.
b Most likely cytogenetic location of marker, according to draft genome sequence data.
c Heterozygosity of each marker, as estimated from the entire study sample.
d LODs were converted into nominal P values by multiplying by 2loge10 and then determining significance from x
2 tables, taking
into account the one-sided nature of the linkage test, as described elsewhere (Lander and Kruglyak 1995).
being investigated. Using multipoint data from all 126
ASPs, we were able to exclude 96% of all regions
scanned from containing a locus with a ls of 3, and
91% from containing a locus with a ls of 2.5 (table
5). The investigated regions of chromosomes 18, 19, 21,
and 22 could be entirely excluded from containing a
locus with a ls of 2 under each of the diagnostic
schemes (fig. 2). The X chromosome could be completely
excluded for a ls of 2 under the narrow diagnostic
scheme. This includes the Xp22 region implicated by
MLS analyses of brother-sister pairs, but the evidence
for exclusion of this region came exclusively from the
brother-brother pairings.
Discussion
We have performed the first genomewide scan for loci
influencing susceptibility to ADHD. Although some re-
searchers have suggested the presence of a major gene
effect predisposing to this disorder (Faraone et al. 1992),
our data indicate that this is highly unlikely. Using allele-
sharing methods, we were able to exclude the vast ma-
jority of the genome from containing a locus with a ls of
2.5 in our sample, which was specifically ascertained
for familial ADHD. Therefore, the high heritability of
ADHD is probably accounted for by multiple loci with
small-to-moderate effect sizes. Note that we do not dis-
count the possibility of rare instances in which extended
families segregate apparentlymonogenic forms ofADHD,
as is observed in other childhood learning disorders (see
Fisher and Smith 2001; Lai et al. 2001). Nevertheless, we
do conclude that there is unlikely to be a single major
gene effect of relevance to the general population of
ADHD cases. MLS mapping in our sample implicated
several regions that may contain loci of more moderate
effect involved in ADHD susceptibility—in particular,
5p12, 10q26, 12q23, and 16p13. However, none of these
exceeded conventional thresholds for genomewide signif-
icance. Therefore, we caution against interpreting the pre-
sent findings as more than early indications of potential
regions of gene locations; additional studies in larger sam-
ples will be necessary to explore further the possible roles
of these chromosomal regions in ADHD.
Prior to the present study, investigations of the mo-
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Figure 1 LOD score plots from multipoint analyses of the whole genome in ASPs with ADHD. A, MLS analyses for “narrow” and
“broad” diagnostic schemes. B, QTL analyses for total symptom count derived from clinical interview. Cumulative distance in Haldane
centimorgans is displayed along the bottom, with chromosome numbers at the top. Peak LOD scores 11 are summarized in table 4.
lecular genetic basis of ADHD have focused only on
candidate genes, mostly those involved in the dopami-
nergic and serotoninergic systems. Having undertaken
a complete genomewide analysis, we have been able to
assess the likely contributions of each of the suggested
candidate genes in our sample (table 6). Of 36 possible
candidates, 29 could be excluded from having a ls of
2 with the “narrow” and/or “broad” classification of
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Table 4
Regions Yielding Peak Multipoint LOD Scores 1 in MLS or QTL Analyses of ADHD ASPs
CHROMOSOME
POSITION
(cM)a
MOST LIKELY
CYTOGENETIC
LOCATIONb NEAREST MARKERc
VALUE IN MLS ANALYSIS
UNDER DIAGNOSTIC SCHEME
Narrow Broad
QTL
D4-TOT
LOD Pd LOD Pd LOD Pd
5 65–68 5p12 D5S418 1.05 .0141 1.04 .0145
8 5–19 8p23 D8S504–D8S550 .69 .0373 1.20 .0094
9 94–97 9q22 D9S283 1.38 .0059 1.05 .0140
10 193 10q26 D10S212 1.32 .0069 1.66 .0028
11 151 11q25 D11S1320 .95 .0181 1.07 .0132
12 0–22 12p13 D12S352–D12S336 .79 .0282 2.60 .0003
12 130–131 12q23 D12S78–D12S79 1.54 .0039 1.16 .0104
12 165 12q24 D12S324 .89 .0212 1.09 .0126
13 0 13q12 D13S175 1.13 .0111 .95 .0184
13 103 13q33 D13S1265 1.04 .0143
16 14 16p13 D16S3075 .75 .0311 1.51 .0042
X 0 Xp22 DXS9895 1.03 .0147 .95 .0182
NOTE.—The table lists only those regions that gave a LOD 1 in at least one of the three analyses (narrow, broad, or
D4-TOT). For these regions, LOD scores and P values of linkage peaks are shown for all analyses yielding .P ! .05
a Haldane centimorgans from the most p-terminal genome-scan marker of the chromosome to peak of linkage.
b Most likely cytogenetic location of highest peak, according to draft genome-sequence data.
c Genome-screen marker(s) nearest to the peak of linkage.
d Nominal P values were calculated from LODs as in table 3.
affection status. It is worth noting that both DRD4 and
DAT1, the most well-studied of these candidates (e.g.,
Curran et al. 2001; Faraone et al. 2001), could be
strongly excluded for such an effect size, regardless of
diagnostic scheme. This is consistent with our earlier
investigations of these genes in this ASP sample andwith
the genotype relative risks reported in the literature
(Smalley et al. 1998; Palmer et al. 1999). Thus, our
findings support the view that, although one or both of
these two genes may be involved in ADHD, they make
only a minor contribution to the overall genetic sus-
ceptibility. Seven candidate genes could not be excluded
for a ls of 2, under either diagnostic scheme: DRD5,
HTR1A, HTR1B, HTR1E, CALCYON, 5HTT, and
SNAP25. The regions containing the DRD5, CAL-
CYON, and 5HTT genes, in fact, yielded positive LOD
scores in exclusion mapping, given this ls. The DRD5
gene maps in the vicinity of D4S403, which was one of
the markers yielding a single-point LOD score 11 in
MLS analyses (table 3), although the multipoint LOD
score was just below this threshold (fig. 1). Similarly,
the 5HTT gene, which encodes a sodium-dependent se-
rotonin transporter, maps in a region of 17q11.2 that
gave a multipoint MLS peak of 0.95 in our screen (fig.
1). Finally, the CALCYON gene, which encodes a
DRD1 interacting protein, coincides with the strongest
MLS result of the screen, in 10q26 (table 4). These
results may be helpful in guiding further targeted studies
of this set of known candidate genes.
The genome-scan ASPs contained an excess of af-
fected males, consistent with epidemiological studies of
ADHD prevalence rates (Cantwell 1996; Swanson et al.
1998). Previous investigations of familial clustering in
this sample suggested that the observed sex differences
are probably not attributable to a major X-linked gene
but are more consistent with a model in which females
require a greater loading of familial factors before they
develop ADHD (Smalley et al. 2000). This hypothesis
was supported by the molecular genetic analyses, which
allowed us to exclude the X chromosome from con-
taining a gene of major effect in brother-brother pairs.
Although we did find some evidence for a possible X-
linked locus at Xp22, this came exclusively from
brother-sister pairs. Note that our sample lacked power
for detection of sister-sister effects, because of the very
small number of sister-sister pairs. It is unclear what
biological mechanism could account for a genetic effect
that is present in brother-sister pairs but absent in
brother-brother pairs.
Diagnosis of ADHD is based on exceeding symptom
thresholds for HI and/or I dimensions. As such, the dis-
order is sometimes viewed as one extreme of a quan-
titatively distributed trait, leading to the hypothesis that
genetic risk factors for ADHD might be equivalent to
the QTLs underlying symptom variability in the normal
population. However, since the DSM classification sys-
tem is specifically formulated with reference to disorder,
DSM-IV–derived symptom counts can be of limited use
for describing variability in unaffected individuals, the
majority of whom show no ADHD symptoms and
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Table 5
Nonparametric Exclusion Mapping in ADHD ASPs
CHROMOSOME
PROPORTION EXCLUDEDa
(%)
Narrow Diagnostic Scheme Broad Diagnostic Scheme
ls p 2 ls p 2.5 ls p 3 ls p 2 ls p 2.5 ls p 3
1 58 83 91 81 95 100
2 63 80 93 53 80 90
3 79 89 96 93 100 100
4 75 85 88 83 93 100
5 68 84 90 78 90 93
6 86 95 100 94 100 100
7 60 94 100 80 92 97
8 52 70 83 53 76 92
9 38 58 77 69 100 100
10 65 83 92 75 94 95
11 64 84 88 77 87 89
12 25 66 74 67 77 85
13 83 95 97 81 97 100
14 54 89 100 85 100 100
15 72 100 100 91 100 100
16 33 47 76 32 59 86
17 58 78 87 54 70 83
18 100 100 100 100 100 100
19 100 100 100 100 100 100
20 39 71 92 71 93 100
21 100 100 100 100 100 100
22 100 100 100 100 100 100
X 100 100 100 96 100 100
Genomeb 66 84 92 77 91 96
a Regions could be excluded if they yielded a LOD score of !2.00.
b Proportion of entire genomewide scan.
would consequently score 0 out of 18. Furthermore, a
definite or probable ADHD diagnosis requires the pres-
ence of at least five of nine symptoms in either the HI
or the I domain, so there may still be significant vari-
ability in DSM-IV symptom count, even within a se-
verely affected population. This was indeed the case
within the ASP sample of the present study, and it was
apparent that familial factors made at least a modest
contribution to this observed variability in severity. We
therefore investigated the total symptom count with a
QTL approach in our ASP sample, in analyses that were
complementary to the qualitative MLS analyses. Note
that these investigations did not rely on assuming any
specific genetic model for ADHD susceptibility. Such
QTL analyses might identify some loci that only act to
modify severity within an affected population (i.e., their
action is conditional on the presence of ADHD). Alter-
natively, these analyses may point to loci that would
also influence appropriate indices of HI or I behavior
in the normal population and could be viewed as overall
risk factors for ADHD.
As shown in tables 3 and 4, in general, the qualitative
and quantitative analyses did not tend to highlight the
same regions of the genome, which might suggest (as
discussed above) the presence of some QTLs whose ef-
fects are only relevant within an ADHD population. An
alternative interpretation could be that the quantitative
phenotype is more closely related to the HI dimension,
since most of the variability in D4-TOT reflects varia-
bility in HI symptoms (see the “Subjects and Methods”
section), whereas the qualitative classifications represent
overall risk. However, phenotypic studies of these ASP
families suggest that familial variance unique to the HI
domain is likely to be small (Smalley et al. 2000). Given
associated problems of multiple testing and sample size
constraints, we did not divide our data set into subtypes
or analyze independent dimensions for linkage, so these
issues await clarification in a larger set of families. It is
also probable that a number of chromosomal regions
implicated by either qualitative or quantitative analyses
may be false positives. Notably, the strongest linkage
with the DSM-IV total symptom count measure, on
12p13, did show reasonable concordance with the qual-
itative analyses. Specifically, this region of 12p13 was
also implicated by MLS methods, with a single-point
LOD score 11 (table 3) and a multipoint peak of 0.79
(fig. 1 and table 4) for the narrow diagnostic scheme.
Again, additional experiments in larger samples may
Table 6
Exclusion Mapping of Regions Containing Candidate Genes in ADHD ASPs
CHROMOSOME
MOST LIKELY
CYTOGENETIC
LOCATION MARKERSa
EXCLUSION LOD UNDER SCHEMEb
GENE Narrow Broad
EXCLUDED
UNDER
SCHEMEc
Symbol Name ls p 2 ls p 2.5 ls p 3 ls p 2 lsp 2.5 lsp 3 Narrow Broad
1 HTR6 Serotonin receptor 6 1p36.13 D1S199–D1S234 2.42 3.77 5.02 1.99 3.33 4.51 X
HTR1D Serotonin receptor 1D 1p36.12 D1S199–D1S234 2.42 3.77 5.02 1.99 3.33 4.51 X
2 HTR2B Serotonin receptor 2B 2q37.1 D2S396–D2S206 2.03 3.29 4.38 1.50 2.70 3.78 X
3 HTR1F Serotonin receptor 1F 3p11.1 D3S3681–D3S1271 3.76 5.45 6.86 3.94 5.74 7.25 X X
DRD3 Dopamine receptor D3 3q13.31 D3S1271–D3S1278 2.90 4.21 5.32 2.94 4.36 5.56 X X
4 DRD5 Dopamine receptor D5 4p16.1 D4S2935–D4S403 .63 .08 .50 .78 1.59 2.30
TDO2 Tryptophan 2,3-dioxygenase 4q32.1 D4S424–D4S413 4.65 6.45 7.92 4.89 6.87 8.49 X X
5 SLC6A3 (DAT1) Sodium-dependent dopamine transporter 5p15.33 5pter–D5S1981 4.42 6.04 7.34 5.53 7.52 9.13 X X
HTR1A Serotonin receptor 1A 5q12.3 D5S407–D5S647 1.49 2.72 3.79 1.82 3.17 4.35
HTR4 Serotonin receptor 4 5q33.1 D5S436–D5S410 4.88 6.76 8.30 5.32 7.40 9.11 X X
DRD1 Dopamine receptor D1 5q35.2 D5S400–D5S408 2.37 3.25 3.94 2.73 3.76 4.58 X X
6 HTR1B Serotonin receptor 1B 6q14.1 D6S257–D6S460 .57 1.48 2.32 1.34 2.53 3.62
HTR1E Serotonin receptor 1E 6q15 D6S460–D6S462 .56 1.41 2.17 1.36 2.51 3.55
STX7 Syntaxin (vesicle receptor) 7 6q23.12 D6S262–D6S292 3.46 5.01 6.34 3.08 4.68 6.07 X X
STX11 Syntaxin 11 6q24.3 D6S308–D6S441 3.57 5.06 6.29 3.53 5.12 6.42 X X
7 DDC Dopa decarboxylase 7p12.23 D7S519–D7S502 3.63 5.15 6.41 3.99 5.68 7.09 X X
HTR5A Serotonin receptor 5A 7q36.3 D7S798–D7S550 1.29 2.37 3.32 2.40 3.85 5.11 X
8 SLC18A1 Vesicular monoamine transporter 8p21.3 D8S261–D8S258 3.03 4.62 6.01 3.51 5.28 6.82 X X
9 DBH Dopamine beta-hydroxylase 9q34.2 D9S164–D9S1826 3.37 4.77 5.90 4.62 6.35 7.73 X X
10 HTR7 Serotonin receptor 7 10q23.32 D10S1686–D10S185 1.10 2.00 2.78 2.12 3.35 4.42 X
CALCYON DRD1 interacting protein 10q26.3 D10S21210qter 1.01 .47 .11 1.23 .61 .07
11 DRD4 Dopamine receptor D4 11p15.5 11pter–D11S4046 3.20 4.81 6.22 3.27 4.98 6.47 X X
TPH Tryptophan hydroxylase 11p15.1 D11S902–D11S904 1.32 2.09 2.74 2.18 3.29 4.21 X
DRD2 Dopamine receptor D2 11q23.1 D11S898–D11S908 2.88 4.35 5.61 3.16 4.91 6.38 X X
HTR3A and HTR3B Serotonin receptors 3A and 3B 11q23.2 D11S898–D11S908 2.88 4.35 5.61 3.16 4.91 6.38 X X
13 HTR2A Serotonin receptor 2A 13q14.2 D13S263–D13S153 3.47 4.97 6.23 3.21 4.70 5.98 X X
15 SNAP23 23-kD synaptosomal-associated protein 15q15.2 D15S994–D15S978 2.42 3.65 4.71 2.53 3.88 5.05 X X
17 SLC6A4 (5HTT) Sodium-dependent serotonin transporter 17q11.2 D17S1857–D17S798 .13 .47 1.05 .58 .01 .56
20 SNAP25 25-kD synaptosomal-associated protein 20p12.3 D20S115–D20S186 1.59 2.57 3.40 1.92 3.01 3.94
STX16 Syntaxin 16 20q13.31 D20S100–D20S171 2.97 4.26 5.33 3.26 4.76 6.01 X X
22 COMT Catechol-o-methyltransferase 22q11.21 D22S420–D22S539 2.05 3.12 4.03 3.07 4.44 5.59 X X
SNAP29 29-kD synaptosomal-associated protein 22q11.21 D22S420–D22S539 2.05 3.12 4.03 3.07 4.44 5.59 X X
X MAOA and MAOB Monoamine oxidases A and B Xp11.3 DXS6810–GATA149D04 6.90 10.07 12.76 7.65 11.23 14.29 X X
HTR2C Serotonin receptor 2C Xq23-24 GATA172D05–GATA165B12 4.87 7.15 9.04 5.37 7.99 10.18 X X
a Genome-scan markers flanking the gene, as determined from draft genome sequence data.
b Highest exclusion LOD scores are given for the interval containing each gene.
c X indicates that the interval can be fully excluded from containing a locus of ls2.
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Figure 2 Exclusion mapping of the whole genome in ADHD ASPs for a ls of 2. LOD score plots are shown under narrow and broad
diagnostic schemes. Regions are excluded if they produce a LOD of !2. See tables 5 and 6 for more details. Cumulative distance in Haldane
centimorgans is displayed along the bottom, with chromosome numbers at the top.
address whether this 12p13 QTL does indeed represent
a general risk factor for ADHD.
Given that a significant proportion of ADHD cases
also manifest some form of learning disability (Cantwell
1996; Brown et al. 2001), it is worth assessing the over-
lap between loci implicated here and linkages suggested
by studies of other childhood disorders, such as dys-
lexia, speech and language impairments, and autistic
disorder. It has been suggested that the observed com-
orbidity may reflect common genetic influences (Will-
cutt et al. 2000). In our sample of 126 ASPs, we did
not find evidence for linkage of ADHD to the principle
loci that have been implicated in dyslexia (2p12-16,
6p21, 15q21, or 18p11) (Fisher and Smith 2001; Fisher
et al. 2002) or speech and language disorders (7q31,
16q24, or 19q13) (Fisher et al. 1998; Lai et al. 2001;
SLI Consortium 2002). However, although autism was
a criterion for exclusion from the present ASP sample,
we found that two of the regions identified in our
ADHD genome screen were concordant with two of the
strongest linkage peaks from genomewide analyses of
autistic sib pairs (IMGSAC 2001). The 2q24 locus that
yielded a LOD of 1.00 in single-point MLS analysis is
within 10 cM of the most significant linkage from the
IMGSAC screen, which gave an MLS of 4.8 in strictly
diagnosed autistic pairs (IMGSAC 2001). The 16p13
locus that gave a multipoint MLS of 11.5 in our ADHD
sample is within ∼1 cM of the third-highest linkage from
the IMGSAC study (IMGSAC 2001). Finally, it is per-
haps of interest to note that one linkage peak at 11q25
is within ∼20 cM of a region in 11q23-24 that has been
implicated in Gilles de la Tourette syndrome (Merette
et al. 2000; Simonic et al. 2001).
In conclusion, the present study has provided, for the
first time, a systematic overview of the entire genome
with respect to susceptibility to ADHD. There is un-
likely to be a single major-gene effect in this disorder,
but it is hoped that future analyses in larger samples,
building on the initial data reported here, may even-
tually lead to the identification of allelic variants at a
number of risk loci. An increased understanding of the
genetic basis of ADHD will ultimately lead to improve-
ments in diagnoses and treatment.
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